What's happening
This bill requires the New York Health Commissioner to annually report detailed information on the cost increases of the state's most expensive prescription drugs and obtain manufacturer explanations for significant price hikes.
Why it matters
Shines a light on price drivers. By requiring detailed annual reporting of the drugs with the highest state spending and sharpest price increases, the bill aims to reveal which pharmaceuticals are straining public budgets and why, making it easier to identify patterns of excessive cost growth.
Demands transparency from manufacturers. The legislation compels drug companies to explain the specific reasons behind significant price hikes, including the breakdown of contributing factors like manufacturing, research, marketing, and profits—information not typically disclosed to the public or policymakers.
Supports informed policy responses. With concrete data on net state costs (after rebates and concessions) and manufacturers’ justifications, state officials and lawmakers will be better equipped to scrutinize, regulate, or negotiate drug pricing in the interest of taxpayers and patients.
Potentially influences broader market behavior. By publicizing this information and increasing accountability, the bill could pressure pharmaceutical companies to moderate future price increases or justify them more rigorously, potentially benefiting consumers beyond those covered by state programs.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Track Prescription Drug Price Hikes
Plain English, a few words. Used as the page title.
Sponsors
12 Co-sponsors
1 Multi-sponsor
History
- Referred to health
- Referred to health
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
741
2021-2022 Regular Sessions
IN ASSEMBLY (Prefiled)
January 6, 2021
Introduced by M. of A. D. ROSENTHAL, EICHENSTEIN, COLTON, DICKENS, SEAWRIGHT, CRUZ, COOK, O'DONNELL, SIMON, McDONOUGH, MONTESANO, HUNTER, MAGNARELLI -- Multi-Sponsored by -- M. of A. SALKA -- read once and referred to the Committee on Health
AN ACT to amend the public health law, in relation to requiring the commissioner of health to include in annual reports information regarding the cost and increase in cost of certain prescription drugs
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subdivision 1 of section 277 of the public health law, as amended by section 18 of part A of chapter 56 of the laws of 2013, is amended to read as follows:
1. The commissioner, in consultation with the drug utilization review board, shall undertake periodic reviews, at least annually, of the preferred drug program which shall include consideration of:
(a) the volume of prior authorizations being handled, including data on the number and characteristics of prior authorization requests for particular prescription drugs;
(b) the quality of the program's responsiveness, including the quality of the administrator's responsiveness;
(c) complaints received from patients and providers;
(d) (i) a list of the ten prescription drugs on which the state expends the most money and for which the wholesale acquisition cost has increased by fifty percent or more over the past five years or by ten percent or more during the previous calendar year. The commissioner shall: include the percentage of the wholesale acquisition cost increase for each drug on the list; rank the drugs on the list from those with the largest increase in wholesale acquisition cost to those with the smallest increase; indicate whether each drug was included on the list based on its cost increase over the past five years or during the previ-
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD05122-01-1
A. 741 2
ous calendar year, or both; and provide the state's total expenditure for each drug on the list during the most recent calendar year; and
(ii) a list of the ten prescription drugs on which the state expends the most money and for which the cost to the state, net of rebates and other price concessions, has increased by fifty percent or more over the past five years or by ten percent or more during the previous calendar year. The commissioner shall rank the drugs on the list from those with the greatest increase in net cost to those with the smallest increase and indicate whether each drug was included on the list based on its cost increase over the past five years or during the previous calendar year, or both; and
(iii) a manufacturer of a prescription drug that appears on a list as described in subparagraph (i) or (ii) of this paragraph shall submit to the commissioner a report that explains: (A) all material factors that have contributed to the wholesale acquisition cost increase for such drug including but not limited to materials and manufacturing costs, spending on research and development costs, spending on marketing and advertising, and spending on patient assistance programs; (B) the percentage of the total wholesale acquisition cost increase attributable to each factor; (C) an explanation of the role of each factor in contributing to the wholesale acquisition cost increase; (D) the total revenue and the net profit of the manufacturer for the most recent calendar year; and (E) any additional information the manufacturer chooses to provide related to drug pricing decisions;
(e) the savings attributable to the state, and to each county and the city of New York, due to the provisions of this article;
[(e)] (f) the aggregate amount of supplemental rebates received in the previous fiscal year and in the current fiscal year, to date; and such amounts are to be broken out by fiscal year and by month;
[(f)] (g) the education and outreach program established by section two hundred seventy-six of this [article] title.
§ 2. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.